In 2021, mobocertinib was FDA-approved as the first drug for NSCLC patients with locally advanced or metastatic disease that had an EGFR exon 20 insertion mutations and progressed with platinum-based chemotherapy. Here, EGFR is linked to metastatic neoplasm.